Loading...
•
Jun 30, 2022
Twist Bioscience Q3 2022 Earnings Report
Reported record revenue with a 60% increase year-over-year and increased revenue guidance for full year fiscal 2022.
Key Takeaways
Twist Bioscience reported record revenue of $56.1 million for the third quarter of fiscal 2022, a 60% increase compared to the same period in fiscal 2021. The company also increased its revenue guidance for the full year fiscal 2022 to $203 million.
Total orders increased 53% to $59.7 million compared to the third quarter of fiscal 2021.
Shipped products to approximately 1,900 customers, compared to approximately 1,800 in the third quarter of fiscal 2021.
Shipped approximately 163,000 genes during the third quarter of fiscal 2022, compared with approximately 107,000 in the third quarter of fiscal 2021.
Entered into a research, exclusive option and license agreement with Astellas for a Twist-discovered antibody.
Twist Bioscience
Twist Bioscience
Twist Bioscience Revenue by Segment
Revenue by Segment
SynBio Revenue
CapyFin.comNGS Revenue
CapyFin.comBiopharma Revenue
CapyFin.com Forward Guidance
Twist Bioscience provided updated financial guidance for the full fiscal year 2022, expecting revenue to be approximately $203 million.
Positive Outlook
- Revenue is now expected to be approximately $203 million.
- SynBio revenue including Ginkgo Bioworks is expected to be $80 million.
- NGS revenue is estimated to be approximately $97 million.
- Biopharma revenue is estimated to be approximately $26 million.
- Gross margin is expected to be 40% for fiscal 2022
Challenges Ahead
- Operating expenses including R&D and SG&A are expected to be approximately $330 million for the year.
- Net loss is expected to be approximately $250 million, reflecting the impact of the Abveris acquisition in stock-based compensation.
- R&D expense is expected to be approximately $125 million.
- Stock-based compensation is expected to be approximately $80 million.
- Capital expenditures are expected to be in the range of $95 to $100 million, including building out the “Factory of the Future”
Revenue & Expenses
Visualization of income flow from segment revenue to net income